A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Active, not recruiting · Phase 4 · NCT06101095
Conditions: Eosinophilic Oesophagitis
At a glance
- Research payments reported, 2025
- $1.7M
- U.S. investigators named
- 15
- Sites paid
- 13
- Planned or actual enrollment
- 69
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (drug), Placebo (drug)
- Dates
- Started 2023-11-29; completion 2028-02-01
- Results posted
- Not yet
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) * Screening period: Up to 12 weeks before Week 0 * Randomized double-blind period: 24 weeks * Open label period: 104 weeks * Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes …
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $1.7M in research payments for this study in 2025 (94 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John J. Hong, MD Gastroenterology · Fallbrook, CA
- Priya Kathpalia, M.D. Gastroenterology · San Francisco, CA
- Ali Moghani Lankarani, MD Gastroenterology · Jacksonville, FL
- Rami G. El Abiad, M.D. Gastroenterology · Iowa City, IA
- Nirmala Gonsalves, MD Gastroenterology · Chicago, IL
- Nina H. Merel, MD Gastroenterology · Glenview, IL
- Jonathan A. Rosenberg, M.D. Gastroenterology · Gurnee, IL
- Christopher A. Marshall, M.D. Gastroenterology · Worcester, MA
- Neetu Talreja, MD Hospitalist · Detroit, MI
- Karthik Ravi, MD Gastroenterology · Rochester, MN
- Evan S. Dellon, M.D., M.P.H. Gastroenterology · Chapel Hill, NC
- Amelie Collins, M.D., PH.D. Neonatology · Cincinnati, OH
- Kristle L. Lynch Gastroenterology · Philadelphia, PA
- Krishnamurthy Shivshanker, M.D. Gastroenterology · Houston, TX
- Moustafa A. Youssef, M.D. Gastroenterology · Mansfield, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Encore Borland Groover Clinical Res Llc $387,751
- University of Iowa Hospital & Clinics, IA $209,832
- University of North Carolina at Chapel Hill $188,642
- Treasure Valley Medical Research Neetu Talreja $176,553
- Texas Digestive Disease Consultants PLLC Gi Alliance $171,325
- Northwestern University $102,017
- Cincinnati Children's Hospital Medical Center, OH $97,880
- Mayo Clinic Mayo School of Cpd $89,187
- Hospital of Univ of Pennsylvania, PA $85,400
- Clinical Trial Network Llc $55,662
- United Medical Doctors United Gastroenterologists $46,804
- University of Massachusetts School of Medicine $23,031
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $16,992
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.